EMA supports first-line ipilimumab plus nivolumab for NSCLC
medwireNews: The EMA’s Committee for Medicinal Products for Human Use has adopted positive opinions for use of nivolumab plus ipilimumab in patients with metastatic non-small-cell lung cancer (NSCLC) without sensitizing EGFR or ALK alterations.
The immunotherapy agents may be given in Europe together as a first-line therapy in combination with two cycles of platinum-based chemotherapy.
This decision extends the use of nivolumab from its initial use in NSCLC patients with locally advanced or metastatic disease who have previously been treated with chemotherapy.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group